胃肠间质瘤领域新药临床研究的现状与进展  

Current status and progress in novel drug research for gastrointestinal stromal tumors

作　　者：董智[1] 李健 Dong Zhi;Li Jian(Department of Gastrointestinal Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所消化肿瘤内科,恶性肿瘤发病机制及转化研究教育部重点实验室,100142

出　　处：《中华胃肠外科杂志》2020年第9期911-916,共6页Chinese Journal of Gastrointestinal Surgery

摘　　要：伊马替尼开启了胃肠间质瘤(GIST)精准治疗的时代,而近年来面对伊马替尼的耐药,始终缺乏令人满意的治疗药物。近期一系列新药的出现,不仅为打破这一局面带来了新的希望,同时再次验证了GIST药物研发仍需锁定驱动基因作为主要靶点。其中以阿泊替尼和瑞普替尼为代表的新药,显示出了令人惊喜的疗效,同时,其可能带动GIST药物治疗开启新的局面。以不同原发基因突变与继发耐药突变为引导的GIST药物精准治疗,必将取代传统的依据治疗线数的指南推荐。Imatinib has created the era of precise treatment of gastrointestinal stromal tumor(GIST).However,in recent years,there has been a lack of satisfactory drugs for imatinib resistance.Recently,the emergence of a series of new agents not only brings new hope to break this situation,but also verifies that the drug development of GIST treatment still needs to lock the driving gene as the main target.New drugs,such as avapritinib and ripretinib,have shown surprising therapeutic efficacy,which may lead to a new situation in the treatment of GIST.The precise treatment of GIST guided by different primary gene mutations and secondary drug resistance mutations will replace the traditional guidelines based on the number of treatment lines.

关 键 词：胃肠间质瘤 精准治疗 驱动基因 新药研发 

分 类 号：R979.1[医药卫生—药品]